Isolation and Subfractionation of
lasma Membranes to Purify Caveolae
Separately from Lipid Rafts
I. INTRODUCTION
Cellular membranes contain distinct microdomains
with unique molecular topographies, including caveolae
and lipid rafts (
Fig. 1). Caveolae are specialized
flask-shaped invaginated microdomains located on the
cell surface membrane of many cell types that appear
to form through the polymerization of caveolin
(Monier
et al., 1995), have a dynamin collar around
their necks for fission (Oh
et al., 1998), and contain
other molecular machinery for vesicular budding,
docking, and fusion, including VAMP-2, NSF, and
SNAP (Schnitzer
et al., 1995a). In contrast, lipid rafts
are flat domains without the characteristic omegashaped
form of caveolae that suggests possible trafficking
function. Unlike caveolae, which form via
protein-protein interactions, lipid rafts appear to form
in the membrane when highly saturated sphingolipids
self-assemble with cholesterol to pack into a highly
ordered lipid phase (Brown and London, 2000).
Caveolae and lipid rafts may share similar lipids but a
detailed compositional analysis is lacking at this
time.
 |
FIGURE 1 Microdomain structure of the plasma membrane. The plasma membrane contains various
low-density microdomains, predominantly caveolae and lipid rafts rich in GPI-AP, that exist as distinct
regions of the cell surface. Although caveolae and lipid rafts exhibit similar buoyant densities and detergent
resistance, they each contain a distinct protein expression profile that differs from each other as well as from
the rest of the plasma membrane proper. NRTK, nonreceptor tyrosine kinases; ACE, angiotensin-converting
enzyme; VAMP, vesicle-associated membrane protein; NSF, N-ethylmaleimide-sensitive fusion protein;
SNAP, soluble NSF attachment protein;
IP3, inositol 1,4,5-trisphosphate. |
Although easily distinguished morphologically by
electron microscopy, caveolae and lipid rafts were considered
equivalent for many years because similarities
in detergent solubility and density profiles made their
biochemical distinction quite difficult and confounded
attempts to definitively characterize the two domains.
Many of caveolar preparations in wide use were isolated
using one-dimensional separation techniques
that rely on detergent resistance and membrane
density after cell lysis (Sargiacomo
et al., 1993; Smart
et al., 1995). These preparations were later found to be
heavily contaminated not only with membranes
derived from intracellular organellar structures, but
also with lipid rafts enriched in glycosylphosphatidyl
inositol-anchored proteins (GPI-AP) derived from
both the plasma membrane and intracellular membranes
(Oh and Schnitzer, 1999; Schnitzer
et al., 1995b).
As a consequence, early reports demonstrating that
these low-density detergent-resistant membrane
fractions were rich in both GPI-AP and caveolin concluded
that caveolae constituted the GPI-AP-enriched
lipid rafts in the plasma membrane (Sargiacomo
et al.,
1993; Smart
et al., 1995). These data were supported
by the finding that antibodies to GPI-AP can be found
in caveolae by immunocytochemistry (Rothberg
et al.,
1990; Ying
et al., 1992). In contrast, other reports
showed that similar detergent-resistant membranes
rich in GPI-AP could be isolated from cells lacking
caveolin or caveolae (Fra
et al., 1995; Gorodinsky and
Harris, 1995). In addition, it was also shown that past
localization of GPI-AP in caveolae had been induced
artifactually by antibody sequestration resulting from
cross-linking by secondary reporter antibodies
(Fujimoto, 1996; Mayor
et al., 1994). Thus, these early
conflicting data made clear that more sophisticated
methods for isolating caveolae and lipid rafts were
necessary to finally defining the molecular constituents
and structure of these structures.
Since the mid-1990s, caveolae and lipid rafts have
been increasingly recognized as separate domains due,
in part, to the development of a multidimensional
membrane isolation technique. The key to this technique
is the use of positively charged colloidal silica
particles to coat selectively the cell surface membrane before tissue/cell homogenization and centrifugation
through a density gradient to yield the silica-coated
plasma membranes as a membrane pellet. Intracellular
membranes or membranes of other cell types (when
processing tissue) are not silica coated, float on the
gradient, and are thus eliminated from the pellet.
This technique provides highly purified silica-coated
plasma membranes largely free of other contaminating
cellular membranes. Using these membranes as a starting
material, it now becomes possible to isolate a
nearly homogeneous preparation of caveolae (caveolin-
coated small vesicles) either by physical homogenization
or by physiological induction (i.e., budding)
(Oh and Schnitzer, 1999; Schnitzer
et al., 1995b, 1996).
Once free of caveolae, the remaining silica-coated
plasma membranes can subsequently be used to
isolate detergent-resistant, caveolin-free lipid rafts
(Schnitzer
et al., 1995b).
These new preparations have revealed distinctions
between the molecular constituents of caveolae and
lipid rafts. Caveolae appear concentrated in caveolin
but not several GPI-AP, which instead existed in lipid rafts isolated from the same plasma membranes and
devoid of caveolin (Oh and Schnitzer, 1999; Schnitzer
et al., 1995b). In addition, each microdomain contains
a unique set of signaling molecules. For example, caveolae
contain growth factor receptors (e.g., plateletderived
growth factor receptor), whereas lipid rafts
contain immunoglobulin E receptors, T-cell receptors
(TCR), and GPI-AP (Field
et al., 1995; Gorodinsky and
Harris, 1995; Liu
et al., 1997; Montixi
et al., 1998;
Shenoy-Scaria
et al., 1992; Stefanova
et al., 1991; Xavier
et al., 1998). In cells expressing caveolin and caveolae,
the heterotrimeric G protein, G
q, concentrates in caveolae
but not in lipid rafts, whereas G
i and G
s tend to
concentrate in lipid rafts preferentially over caveolae
(Oh and Schnitzer, 2001). The apparent ability of caveolin-
1 to form a complex in the plasma membrane with
G
q, but not G
i or G
s, appears to trap G
q effectively in
caveolae and minimize its presence in lipid rafts. In
cells without caveolae, G
q partitions into lipid rafts
with other G proteins. These findings, discovered
by tissue/cell subfractionation, were confirmed by
immunofluorescence microscopy.
This article describes several protocols based primarily
on a series of past studies (Brown and Rose,
1992; Oh and Schnitzer, 1999; Schnitzer
et al., 1995b;
Smart
et al., 1995) using silica methodology to isolate
first plasma membranes from tissue and cultured cells
prior to further subfractionation to isolate their caveolae
separately from lipid rafts rich in GPI-AP.
II. MATERIALS AND
INSTRUMENTATION
A. Materials
Sodium chloride (Cat. No. BP358), potassium chloride
(Cat. No. BP366), magnesium sulfate (Cat. No.
BP213), glucose (Cat. No. BP350), EDTA disodium salt
(Cat. No. BP120), sodium bicarbonate (Cat. No.
BP328), sucrose (Cat. No. BP220), magnesium chloride
(Cat. No. BP214), Tris (Cat. No. BP152), methanol (Cat.
No. A412), hydrochloric acid (Cat. No. A144), sodium
hydroxide (Cat. No. SS255), sodium carbonate (Cat.
No. BP357), 2-mercaptoethanol (Cat. No. BP176),
Tricine (Cat. No. BP315), Tween 20 (Cat. No. BP337),
silver nitrate (Cat. No. $181), glacial acetic acid (Cat.
No. A38), sodium phosphate dibasic (Cat. No. BP332),
potassium phosphate monobasic (Cat. No. BP362),
potassium phosphate dibasic (Cat. No. BP363), Tygon
tubing (Cat. No. 14-169-1B), razor blades (Cat. No. 12-
640), and 15-ml centrifuge tubes (Cat. No. 05-539-5) are
from Fisher. HEPES (Cat. No. 737 151) and Pefabloc SC
(Cat. No. 1 585 916) are from Roche Applied Science.
2-(N-Morpholine)ethanesulfonic acid (MES) (Cat. No.
M2933), leupeptin (Cat. No. L 2884), O-phenanthroline
(Cat. No. P9375), pepstatin A (Cat. No. P 4265), sodium
nitroprusside (Cat. No. S 0501), E-64 (trans-epoxysuccinyl-
L-leucylamido-[4-guanidino] butane) (Cat. No. E
3132), glycerol (Cat. No. G 5516), potassium acetate
(Cat. No. p 3542), magnesium acetate (Cat. No. M
0631), and EGTA (Cat. No. E 4378) and from Sigma.
Percoll (Cat. No. 17-0891-01) is from Amersham Biosciences.
Protease inhibitor Cocktail I (2004) is from
EMD Biosciences (Cat. No. 539131) Ten percent Triton
X-100 (Cat. No. 28314) is from Pierce. Goat antimouse
IgG-HRP conjugate (Cat. No. NA931) and goat
antirabbit IgG-HRP conjugate (Cat. No. NA934) are
from Amersham. Goat antimouse IgG-bodipy conjugate
(Cat. No. B-2752), goat antimouse IgG-Texas red
conjugate (Cat. No. T-862), goat antirabbit IgG-bodipy
conjugate (Cat. No. B-2766), and goat antirabbit
IgG-Texas red conjugate (Cat. No. T-2767) are from
Molecular Probes. Polyacrylic acid (PAA) (Cat. No.
00627) is from Polysciences Inc. Nycodenz (Cat. No.
AN-7050/BLK) is from Accurate Chemicals. Sprague
Dawley rats (male) are from Charles Riven SW28 tubes
(Cat. No. 344058) and SW55 tubes (Cat. No. 344057) are
from Beckman. Ketamine is from Fort Dodge Animal
Health and xylazine is from Vedco Inc. Nitex filters 53
µm (Cat. No. 3-50/31) and 30µm (Cat. No. 3-30/18) are
from Sefar America Inc. Type "AA" homogenizer (Cat.
No. 3431-E10), type "BB" homogenizer (Cat. No. 3431-
E20), and type "C" homogenizer (Cat. No. 3431-E25)
are from Thomas Scientific. Silk suture (3-0) is from
Ethicon. Aluminum tubing (Cat. No. 89-78K101) is
from McMaster-Carr. The three-way stopcock (Cat.
No. 732-8103) is from Bio-Rad.
B. Instrumentation
Ultracentrifugation is carried out in a Beckman L8-
80, Sorvall Pro 80, or Optima MaxE ultracentrifuge.
Other centrifugation is carried out in a Brinkman
Eppendorf 5415C or IEC Centra MP4R.
C. Perfusion Apparatus
On a ring stand, attach five 60-cc syringes attached to
a series of five three-way stopcocks by way of Tygon
tubing (0.0625in. i.d.). The series of three-way stopcocks
are attached to Tygon tubing with an stainless
steel loop (0.046 in. i.d.) inserted in the middle of the
tubing. The stainless-steel loop is used to regulate the
temperature of the solutions perfused into the rat vasculature
by emersion in temperature-controlled water.
The pressure of flow is measured by a sphygmomanometer
attached to the 60-cc syringes by Tygon
tubing and a single hole rubber stopper. The flow for
perfusion is normally 8 mm of Hg. The flow rate at 25°C is approximately 5 ml/min and at 10°C is 4 ml/min.
III. PROCEDURES
Unless otherwise specified in the protocol, all procedures
should be performed at 4°C and all solutions
must be kept and used ice cold.
Solutions
Buffer PM: 0.25 M sucrose, 1 m
M EDTA, 20 m
M Tricine
in ddH
2O pH to 7.8 with NaOH (filter through
0.45-µm bottle top filter (can be stored at 4°C). For
500ml: 42.79
g sucrose, 0.186
g EDTA (disodium
salt), and 1.79
g Tricine.
Colloidal silica solution: From a 30% positively
charged colloidal silica stock solution, dilute to 1%
with MBS pH 6.0 [pH to 6.0 with NaOH if necessary
and filter through 0.45-µm bottle top filter (can be stored at 4°C). For 300ml: 10ml stock silica in
490 ml MBS, pH 6.0, with pH strips (usually you do
not have to adjust pH).
Cytosolic buffer: 25m
M potassium chloride, 2.5m
M magnesium acetate, 5m
M EGTA, 150m
M potassium
acetate, 25m
M HEPES in ddH
2O pH to 7.4
with KOH and filter through 0.45-µm bottle top
filter (can be stored at 4°C). For 500ml: 0.93g KCl,
0.27 g Mg(C
2H
3O
2)
2·4H
2O, 0.95 g C
14H
24N
2O
10, 7.36 g
KC
2H
2O
2, and 2.98 g HEPES.
250mM HEPES, pH 7.4: 29.8g in 450ml ddH
2O, pH to
7.4 with NaOH, bring to 500 ml with ddH
2O
1M KCl: 7.46 g in 100 ml ddH
2O
20mM KCl: 200µl 1
M KCl, bring to 10ml with ddH
2O
Mammalian Ringer's solution (without calcium):
114m
M sodium chloride, 4.5m
M potassium chloride,
1 m
M magnesium sulfate, 11m
M glucose,
1.0 m
M sodium phosphate (dibasic), 25 m
M sodium
bicarbonate in ddH
2O pH to 7.4 with HCl (filter
through 0.45-µm bottle top filter (can be stored at
4°C). For 2 liters: 13.32g NaCl, 0.67g KCl, 0.492g
MgSO
4·7H
2O, 3.96g glucose, 0.28g Na
2HPO
4, and
4.20 g NaHCO
3.
MES buffered saline (MBS): 20 m
M MES, 135 m
M NaCl
in ddH
2O pH to 6.0 with NaOH [filter through 0.45-
µm bottle top filter (can be stored at 4°C). For 2
liters: 7.8 g MES and 14.6 g NaCl.
80% Nycodenz: 8ml 100% Nycodenz, 200µl 1
M KCl
bring to 10 ml with ddH
2O
75% Nycodenz: 7.5ml 100% Nycodenz, 200µl 1
M KCl
bring to 10 ml with ddH
2O
70% Nycodenz: 7ml 100% Nycodenz, 200µl 1
M KCl
bring to 10 ml with ddH
2O
65% Nycodenz: 6.5ml 100% Nycodenz, 200µl 1
M KCl
bring to 10 ml with ddH
2O
60% Nycodenz: 6ml 100% Nycodenz, 200µl 1
M KCl
bring to 10 ml with ddH
2O
100% Nycodenz (v/w): 100g Nycodenz in 100ml of
ddH
2O
70% Nycodenz/sucrose/HEPES: 7ml 100% Nycodenz,
1 ml 60% sucrose, 1 ml 250m
M HEPES, pH 7.4,
200 µl 1
M KCl bring to 10 ml with ddH
2O
65% Nycodenz/sucrose/HEPES: 6.5ml 100% Nycodenz,
1 ml 60% sucrose, 1 ml 250m
M HEPES, pH
7.4, 200 µl 1
M KCl bring to 10ml with ddH
2O
60% Nycodenz/sucrose/HEPES: 6ml 100% Nycodenz,
1 ml 60% sucrose, 1 ml 250m
M HEPES, pH 7.4,
200 µl 1
M KCl bring to 10 ml with ddH
2O
55% Nycodenz/sucrose/HEPES: 5.5ml 100% Nycodenz,
1 ml 60% sucrose, 1 ml 250m
M HEPES, pH
7.4, 200 µl 1
M KCl bring to 10ml with ddH
2O
30% Percoll in buffer PM: Mix 30ml of stock Percoll
with 70ml of buffer PM
Phosphate-buffered saline (PBS): 137m
M sodium chloride, 2.7m
M potassium chloride, 4.3 m
M sodium phosphate (dibasic), 1.4m
M potassium
phosphate (monobasic) in ddH
2O pH to 7.4. For 1
liter: 8 g sodium chloride, 0.2 g potassium chloride,
0.61 g sodium phosphate (dibasic), 0.2g potassium
phosphate (monobasic).
Polyacrylic acid: From 25% stock solution, dilute to
0.1% with MBS, pH 6.0 [pH to 6.0 with NaOH and
filter through 0.45-µm bottle top filter (can be stored
at 4°C)]. For 500ml: 2ml stock 25% polyacrylic acid
in 480ml MBS, pH 6.0, pH to 6.0 and bring to
500ml with MBS pH 6.0.
Potassium phosphate/polyacrylic acid: 4 M potassium
phosphate (dibasic) 2% PAA in ddH
2O pH to 11
with NaOH. For 10 ml: 6.96 g potassium phosphate
(dibasic) and 0.8ml 25% stock polyacrylic acid.
60% sucrose (w/w): 385.95 g sucrose in 200ml ddH
2O,
add 10ml 1
M KCl, after the sucrose has dissolve,
bring to 50ml with ddH
2O
Sucrose/HEPES: 250m
M sucrose, 25m
M HEPES,
20m
M potassium chloride in ddH
2O pH to 7.4
with NaOH and filter through 0.45-µm bottle top
filter (can be stored at 4°C). For 2 liters: 171.16g
sucrose, 11.92 g HEPES and 2.98 g KCl.
60% sucrose (w/w)/20mM KCl: 385.95g sucrose in
200ml ddH
2O, add 10ml 1
M KCl, after the sucrose
has dissolve, bring to 50ml with ddH
2O
35% sucrose (w/w)/20mM KCl: 5.2ml 60% sucrose,
200 µl 1
M KCl, bring to 10ml with ddH
2O
30% sucrose (w/w)/20mM KCl: 4.4ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
25% sucrose (w/w)/20mM KCl: 3.8ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
20% sucrose (w/w)/20mM KCl: 2.8ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
15% sucrose (w/w)/20mM KCl: 2.1ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
10% sucrose (w/w)/20mM KCl: 1.3ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
5% sucrose (w/w)/20mM KCl: 0.7ml 60% sucrose,
200µl 1
M KCl, bring to 10ml with ddH
2O
10% Triton X-100 in PBS
A. Purification of Silica-Coated Plasma
Membranes (P)
1. Perfusion Procedure
- Anesthetize rats with a cocktail of ketamine
(60mg/kg) and xylazine (1.6mg/kg). Perform a
tracheotomy to ventilate the lungs using a
respirator.
- Insert tubing from the perfusion apparatus into the
pulmonary artery via the right ventricle and fasten by tying a 3-0 silk suture around the artery. Cut the
left atrium to allow the flow to exit.
- Perfuse (4 ml/min) with Ringer's for 5 min starting
at room temperature. After 1-1.5 min, begin lowering
the temperature to ~10°C by placing the stainless-
steel loop into an ice-cold bath. Gently drip
ice-cold PBS over the lung to prevent drying. The
remainder of the procedure should be performed at
this cool temperature.
- Perfuse MBS for 1.5 min.
- Perfuse 1% colloidal silica solution for 1.5 min. At
this point, keep the lungs inflated by replacing the
tube attached to the respirator with a syringe and
inflate with 3-5 ml of air.
- Flush with MBS for 1.5 min.
- Perfuse 0.1% PAA for 1.5 min.
- Flush lungs with 8ml of sucrose/HEPES with protease
inhibitor Cocktail I (1×).
- Excise lungs from the animal and keep cold by
immersion in ice-cold sucrose/HEPES with protease
inhibitor Cocktail I (1×).
2. Processing of the Lung
- Finely mince the excised lung mince with a "new"
razor blade on a cold aluminum block embedded in
ice.
- Add 20ml of sucrose/HEPES with protease
inhibitors and place into a type "C" homogenizer
vessel.
- Homogenize for 12 strokes at 1800rpm in a cold
(4°C) room.
3. Purification of Silica-Coated Luminal Endothelial
Cell Plasma Membrane (P)
- Filter the homogenate through a 53-µm Nytex filter,
followed by a 30-µm Nytex filter.
- Remove 200µl from the filter solution, label
"homogenate," and store at -20°C. Adjust the
volume of the remaining solution to 20 ml with cold
sucrose/HEPES with protease inhibitors.
- Add an equal volume of 100% Nycodenz and mix
(this is enough for two SW28 tubes). Layer onto a
70-55% continuous Nycodenz sucrose/HEPES gradient
(form by placing 3ml of 70, 65, 60, and 55
Nycodenz sucrose/HEPES and carefully swirling
the solution, holding the tube at a 45° angle about
5-10 times).
- Top with sucrose/HEPES with protease inhibitors.
Spin at 15,000rpm for 30min at 4°C in a SW28 rotor.
Aspirate off the supernatant. Resuspend the pellet
in 1 ml MBS. Add equal volume of 100% Nycodenz
and mix.
- Layer onto a 80-60% continuous Nycodenz gradient
(form by placing 350 µl of 80, 75, 70, 65, and 60%
Nycodenz and twirling tube about 5-10 times). Top
with 20mM KCl. Spin at 30,000rpm for 30min at
4°C in a SW55 rotor. Aspirate and discard the supernatant.
Resuspend the pellet in 1 ml MBS and label
as "P." Store at -20°C.
4. Isolation of Silica-Coated Plasma Membranes
from Cultured Cells (Monolayer)
This protocol is written for T75 flasks; alter proportionately
for larger or smaller flasks. All parts of the
procedure need to be performed on ice or in a 4°C room.
- Wash cell monolayer three times with MBS.
- Overlay with 1% ice-cold colloidal silica solution
and incubate for 10min. Wash cell monolayer three
times with MBS.
- Overlay with 0.1% PAA and incubate for 10 min.
Wash cell monolayer three times with MBS.
- Add 5ml of sucrose/HEPES with protease
inhibitors (1×). Scrape cells and place in 15-ml centrifuge
tube. Centrifuge 1000g for 5 min at 4°C.
- Bring to 1 ml with cold sucrose/HEPES with protease
inhibitors (1×) (you can use up to six T75 flasks
per 1 ml of cold sucrose/HEPES with protease
inhibitors).
- Place in type "AA" homogenizer vessel. Homogenize
with corresponding grinder for 20 strokes at
1800rpm.
- Remove 100 µl and label as "homogenate" and store
at -20°C.
- Add an equal volume of 100% Nycodenz and mix
(SW55 tube). Layer onto a 70-55% continuous
Nycodenz sucrose/HEPES gradient (form by
placing 350µl of 70, 65, 60, and 55% Nycodenz
sucrose/HEPES and carefully twirling tube as
described earlier).
- Top with sucrose/HEPES with protease inhibitors.
Spin at 30,000rpm for 30 min at 4°C in a SW55 rotor.
Aspirate off the supernatant. Resuspend the pellet
in 1 ml MBS and label as "P." Store P at -20°C.
B. Isolation of Caveolae (V)
1. Isolation of Caveolae (V) (in the Presence of
Detergent)
- Take 900 µl "P" (as per step 5 of Section III,A,3 or
step 6 of Section III,A,4), add 100µl 10% Triton X-100,
and mix. Save 100 µl "P." Mix on nutator for 10 min
at 4°C. Place in type "AA" homogenizer vessel. Homogenize with corresponding grinder for 20
strokes at 1800 rpm.
- Bring to 40% sucrose (w/w) with 60% sucrose
(w/w)/20mM KCl (takes about 1.5ml). Layer with
discontinuous 35-0% sucrose (w/w)/20 mM KCl gradient
(350µl of 35, 30, 25, 20, 15, 10, and 5 % sucrose / 20
mM KCl and 20 mM KCl).
- Spin at 50,000rpm for 4h at 4°C in a MLS-50
rotor.
- Collect the band between 10 and 15% sucrose
(w/w) density. Dilute the band material two to three
times with MBS and spin at 15,000rpm for 2h at 4°C. Resuspend pellet in 100µl MBS, pH 6.0, and label as
"V"
- Collect and resuspend membrane pellet from
step 3 in 1 ml MBS and label as "P-V."
- Store both fractions at -20°C.
2. Isolation of V" (Detergent Free)
- Process as in Section III,B,1 except omit the addition
of Triton X-100 and homogenize for 60 strokes.
Label floated caveolae as "V'" (V prime).
- Collect and resuspend membrane pellet from step 3
in Section III,A,4 and label as "P-V.'"
- Store V' and P-V' at -20°C.
C. Isolation of Budded Caveolae (Vb)
(Caveolae Isolation without Physical
Disruption)
1. Isolation of Rat Lung Cytosol
- Perfuse rat lung as described in Section III,A using
steps 1, 2, 3, 8, and 9 only.
- Homogenize lung in cytosolic buffer (2-3×, v/w)
for 10 strokes at 1800 rpm.
- Spin at 35,000rpm for 1 h at 4°C in a SW55 rotor.
Place supernatant over PD-10 column and collect
first peak. Aliquot (1 ml), label at "rat lung cytosol,"
and store at -80°C.
2. Isolation of "Vb"
- Incubate "P" or "PM" (PM described later) (20-
50µg/ml) with rat lung cytosol (1-5mg/ml) for 1 h
at 37°C.
- Bring to 40% sucrose (w/w) with 60% sucrose
(w/w)/20mM KCl solution. Layer with discontinuous
35-0% sucrose 20mM KCl gradient (as
described in Section III,B; 350µl each layer).
- Spin at 30,000rpm overnight at 4°C in a SW55 rotor.
Collect the band between 10 and 15% sucrose
(w/w) density. Dilute the band material two to
three times with MBS and spin at 15,000rpm for 2 h at 4°C. Resuspend pellet in 100µl MBS and label
as "Vb."
- Collect and resuspend membrane pellet from step 2
in 1 ml MBS and label as "P-Vb." Store at -20°C.
D. Isolation of Lipid Rafts (LR)
Isolation of LR
- Resuspend membrane pellet (P-V) from Section
III,B in 1 ml of ice-cold MBS, pH 6.0. Add equal
volume of potassium phosphate/polyacrylic acid
(pH should be greater than 9.5). Mix well.
- Sonicate at maximum output for 10 bursts of 10s
each. Cool on ice between bursts. Mix using nutator
at room temperature for 8h and then sonicate as
described earlier except use 5- to 10-s bursts.
- Add Triton X-100 to a final concentration of 1%. Mix
on nutator for 10 min at 4°C and then place in a type
"AA" homogenizer vessel.
- Homogenize with corresponding grinder for 30
strokes at 1800rpm. Bring to 40% sucrose (w/w)
using 60% sucrose (w/w)/20 mM KCl and layer with
discontinuous 35-0% sucrose (w/w) with 20mM KCl using 350µl solution per layer as described
Section III,A.
- Centrifuge at 30,000 rpm overnight at 4°C in a SW55
rotor.
- Collect band between 10 and 15% sucrose (w/w)
density. Dilute the band material two to three times
with MBS and centrifuge at 15,000rpm for 2h at
4°C. Resuspend pellet in MBS, label as "LR," and
store at -20°C.
- Collect the stripped membrane pellet from step
5 and resuspend in MBS. Label as "SP" and store at
-20°C.
E. Isolation of Plasma Membrane-Enriched
Fraction (PM)
Isolation of PM from Tissue
- Perfuse rat lung as described in Section III,A
using steps 1, 2, 3, 8, and 9 only.
- Process rat lung as described in Section III,A
except use 3 ml of buffer PM and type "BB" homogenizer
vessel for step 2.
- Filter the homogenate through a 53-µm Nytex
filter and then through a 30-µM Nytex filter.
- Remove 200µl from the filter solution, label as
"homogenate," and store at -20°C. Centrifuge the
remaining supernatant at 1000g for 10min at 4°C. Save supernatant on ice. Resuspend the pellet in 3 ml
buffer PM and repeat centrifugation. Pool the two
supernatants.
- Adjust the volume to 7ml with buffer PM and
then add 3ml to make a 30% Percoll solution. Centrifuge
at 84,000g for 45min at 4°C (no brakes) in
MLS50 rotor. Collect the band around two-thirds to
three-fourths from bottom of the tube. Dilute the band
material two to three times with PBS and centrifuge at
15,000rpm for 2h at 4°C. Resuspend pellet in 100µl
PBS, label as "PM," and store at -20°C.
Isolation of PM from Cultured Cells
This protocol is written for T75 flasks, alter proportionately
for larger or smaller flasks. All parts of the
procedure need to be performed on ice or in a 4°C room.
- Wash cell monolayer three times with cold buffer
PM.
- Add 5 ml of cold buffer PM with protease inhibitors
(1×). Scrape cells and place in 15-ml centrifuge tube.
Centrifuge at 1000g for 5min at 4°C.
- Bring to 1 ml with cold buffer PM with protease
inhibitors (1×) (you can use up to six T75 flasks per
1 ml of cold buffer PM with protease inhibitors).
- Place in type "AA" homogenizer vessel. Homogenize
with corresponding grinder for 20 strokes at
1800rpm.
- Remove 100 µl, label as "homogenate," and store at
-20°C.
- Centrifuge the remaining supernatant at 1000g for
10min at 4°C. Save supernatant on ice. Resuspend
the pellet in 1 ml buffer PM and repeat centrifugation.
Pool the two supernatants.
- Adjust the volume to 3.5ml with buffer PM and
then add 1.5ml to make a 30% Percoll solution.
Centrifuge at 84,000g for 45min at 4°C (no brakes)
in MLS50 rotor. Collect the band around two-thirds
to three-fourths from bottom of the tube. Dilute
the band material two to three times with PBS and
centrifuge at 15,000rpm for 2h at 4°C. Resuspend
pellet in 100µl PBS, label as "PM," and store at
-20°C.
E Isolation of Triton-Resistant
Membranes (TRM)
Isolation of TRM from Tissue
- Perfuse rat lung as described in Section III,A using
steps 1, 2, 3, 8, and 9 only.
- Process rat lung as described in Section III,A except
add 1% Triton X-100 to sucrose/HEPES solution in
step 2.
- Filter the homogenate through a 53-µM Nytex filter
and then through a 30-µM Nytex filter.
- Remove 200µl from the filter solution, label as
"homogenate," and store at -20°C. Bring the
remaining supernatant to 40% sucrose (w/w)/
20mM KCl. Layer with discontinuous 35-0%
sucrose (w/w)/20mM KCl gradient (3ml each of
35, 30, 25, 20, 15, 10, and 5% sucrose (w/w)/20mM KCl and 20mM KCl as described in Section III,B).
- Centrifuge at 15,000rpm overnight at 4°C in SW28
rotor. Collect the band between 10 and 15% sucrose
(w/w) density. Dilute the band material two to
three times with PBS and centrifuge at 15,000rpm
for 2h at 4°C. Resuspend pellet in PBS, label as
"TRM," and store at -20°C.
Isolation of TRM from Cells
This protocol is written for T75 flasks; alter proportionately
for larger or smaller flasks. All parts of the
procedure need to be performed on ice or in a 4°C room.
- Wash cells three times with 1X PBS.
- Scrape cells and place in 15-ml conical tube. Centrifuge
at 1000g for 5min at 4°C.
- Resuspend pellet in 1 ml of 1X PBS. Remove 100µl,
label this cellular homogenate as "H," and store at
-20°C.
- To the remaining H add Triton X-100 to 1%
(100 µl of 10% Triton X-100) for a total volume of
1 ml.
- Place in type "AA" homogenizer vessel. Homogenize
with corresponding grinder for 20 strokes at
1800rpm.
- Bring to 40% sucrose (w/w)/20mM KCl and layer
with discontinuous 35-0% sucrose (w/w)/20mM KCl and centrifuge as described in Section III,B.
- Collect the band between 10 and 15% sucrose
(w/w) density. Dilute the band material two to
three with PBS and centrifuge at 15,000rpm for 2 h
at 4°C. Resuspend pellet in PBS, label as "TRM,"
and store at -20°C.
Isolation of TRM from PM
- Isolate PM as described in Section III,E.
- Bring pelleted PM to 1 ml with buffer PM.
- Remove 100µl, label as "PM," and store at -20°C.
- To the remaining PM add Triton X-100 to 1% (100µl
of 10% Triton X-100) with a total volume of 1 ml.
Mix on nutator for 10min at 4°C.
- Bring to 40% sucrose (w/w)/20mM KCl, layer with
discontinuous 35-0% sucrose (w/w)/20mM KCl,
and centrifuge as described in Section III,B.
- Collect the band between 10 and 15% sucrose
(w/w) density. Dilute the band material two to three times with PBS and centrifuge at 15,000rpm
for 2h at 4°C. Resuspend pellet in PBS, label as
"TRM," and store at -20°C.
IV. POTENTIAL PITFALLS
- When utilizing cellular membrane subfractions,
a rigorous quality control protocol must be applied. It
is very important that one first check the purity of the
starting material to confirm that the preparation is
enriched in markers of the desired membrane material
and depleted in markers of other membrane-bound
cellular organelles. At the very least, preparations
should be checked for markers of the major
microdomain components of the plasma membrane,
such as caveolae, lipid rafts, adhesion complexes, and
the plasma membrane proper, as well as for contaminating
intracellular organellar membranes. A good
plasma membrane preparation should be enriched
15- to 20-fold in cell surface marker proteins, such as
caveolin-1, GPI-AP, integrins, and ion transporters. It
should also be depleted by 15- to 20-fold in protein
markers expressed in nuclei (ran, transportin), Golgi
(p58, β-COP), lysosomes (lamp1), and mitochondria
(cytochrome c). Likewise, caveolar preparations must
be enriched in caveolar proteins, such as caveolin-1,
Gq, and eNOS. LR should be enriched in GPI-AP but
lack caveolin-1 expression. In addition, it is also very
important to monitor the mass balance of all proteins.
For plasma membrane preparations isolated by the
silica method, this can be accomplished by examining
by Western analysis the proteins left behind in the
P-V fraction (containing LR and remaining plasmalemma
proper) and comparing them to the protein
expression in the P and V fractions to verify that the
signal for all three fractions can be accounted for by
the fractionation.
- It is very important to maintain the recommended
temperatures as presented in these protocols,
especially when working with Triton X-100 solubilization.
Any increases in temperature may solubilize a
greater number of proteins, which may alter the final
protein profile.
- One needs to use the correct pH for the solutions,
especially those associated with cationic silica particles,
as alterations in pH will affect the binding of the
silica to the luminal plasma membrane.
- All solutions must be filtered with at least a
0.45-µm filter to ensure that they remain relatively free
of contaminants and aggregates.
- Do not mix phosphate solutions with solutions
containing colloidal silica, as this will cause the silica
to precipitate.
- When perfusing rat organs, be careful to avoid
getting air bubbles in the line of the perfusion apparatus,
as this will interfere with the vessel lumen-coating
procedure and decrease the amount of isolated
material.
V. DISCUSSION
The overall goal of these procedures is to excise
microdomains specifically from cellular membranes,
in this case, from plasma membranes. To isolate any
microdomain from a membrane, certain critical criteria
are necessary to increase efficiency and purity. First,
the microdomain excision must be highly selective. In
most cases, however, this cannot be accomplished in
one step. One must start with the appropriate highly
purified membrane fraction containing the desired
microdomain and then process this material to specifically
excise and, if necessary, differentially isolate
the desired microdomain away from other similarly
excised domains.
If detergent-resistant microdomains were unique to
the plasma membrane, then contamination with other
organellar membranes would be rendered irrelevant.
However, that seems quite unlikely given that newly
synthesized GPI-AP also acquire resistance to detergent
extraction upon entering the trans-Golgi compartment;
in fact, TRM were first isolated from
cultured MDCK cells as a tool for studying this maturation
process (Brown and Rose, 1992). Hence, it is
clearly advantageous to start with purified plasma
membranes when trying to purify caveolae or other
cell surface microdomains. The silica-coating method
described here permits one to first isolate plasma
membranes to high purity before further subfractionation
to purify caveolae separately from other plasmalemmal
microdomains (
Fig. 2). To isolate the
luminal endothelial cell plasma membrane directly
from tissue, the tissue is first perfused with polycationic
colloidal silica particles that selectively coat this
luminal surface to increase the membrane density.
Then, after electrostatic cross-linking and cation
quenching, the tissue is homogenized and subjected to
a series of centrifugations to sediment the higher
density silica-coated membranes away from the other
tissue components that are not silica coated and have
much lower densities. Electron microscopy shows
large silica-coated membrane sheets in these pellets.
 |
FIGURE 2 Two-step silica coating-based methodology for isolating plasma membrane caveolae. To
purify endothelial plasmalemmal caveolae, the luminal endothelial cell membrane is first coated with positively
charged colloidal silica particles to create a stable pellicle that specifically marks this membrane and
facilitates its purification by density centrifugation of tissue homogenates. These pelleted membranes have
many caveolae attached on the side of the membranes opposite to the silica coating that may be stripped
from the endothelial membranes by shearing during homogenization at 4°C in the presence of Triton X-100.
Further centrifugation through a sucrose density gradient yields a homogeneous population of distinct caveolar
vesicles. |
This procedure can also be performed on cultured cells
(Schnitzer and Oh, 1996), even as a cell monolayer
where the top membrane surface opposite to the
plastic can be coated and purified. Using this method,
the plasma membranes are enriched to levels exceeding
standard subcellular fractionation techniques (e.g.,
Percoll) (Oh and Schnitzer, 1999) with minimal contamination
from marker proteins of various intracellular
organelles (nuclei, endoplasmic reticulum, Golgi,
and mitochondria), as well as nonendothelial cells in
the tissue (
Fig. 3B; compare PM to P) (Schnitzer
et al.,
1995b) that are commonly present in other published
preparations (Chang
et al., 1994; Lisanti
et al., 1994; Oh
and Schnitzer, 1999; Smart
et al., 1995).
![FIGURE 3 Molecular mapping of luminal plasma membrane subfractions. Proteins (5 µg) from the indicated membrane fractions were subjected to SDS-PAGE followed by electrotransfer to filters for immunoblotting with antibodies to the indicated proteins. H, homogenate; P, silica-coated plasma membrane; PM, percollgradient isolated plasma membranes; V, caveolae [V (in the presence of Triton), V' (in the absence of Triton)], P-V, silica-coated plasma membrane stripped of caveolae [P-V (in the presence of Triton), PV' (in the absence of Triton)]; Tx, Triton-soluble phase; AC, Optiprepisolated, caveolin-enriched membranes; U, material not bound to caveolin antibody-coupled magnetic beads after immunoisolation; B, material bound to caveolin antibody-coupled magnetic beads after immunoisolation.](images/v2_pa_s01_c02_f03.jpg) |
FIGURE 3 Molecular mapping of luminal plasma membrane
subfractions. Proteins (5 µg) from the indicated membrane fractions
were subjected to SDS-PAGE followed by electrotransfer to filters
for immunoblotting with antibodies to the indicated proteins.
H, homogenate; P, silica-coated plasma membrane; PM, percollgradient
isolated plasma membranes; V, caveolae [V (in the presence
of Triton), V' (in the absence of Triton)], P-V,
silica-coated plasma
membrane stripped of caveolae [P-V (in the presence of Triton),
PV'
(in the absence of Triton)];
Tx, Triton-soluble phase; AC, Optiprepisolated,
caveolin-enriched membranes;
U, material not bound to
caveolin antibody-coupled magnetic beads after immunoisolation;
B, material bound to caveolin antibody-coupled magnetic beads
after immunoisolation. |
Plasma membranes contain at least two types of
microdomains, caveolae and lipid rafts, that although
distinct in protein and possible lipid composition,
share certain biochemical properties that often confound attempts at generating highly enriched isolates.
Complicating matters further is the fact that caveolae
and lipid rafts may be found on the cell surface not
only as discrete entities, but also closely associated
with each other, in some cases, with lipid rafts in close
enough proximity to caveolae that they are essentially
attached to a caveola at the annulus (
Fig. 1) (Schnitzer
et al., 1995b). Consequently, caveolae isolation
methods that use as a starting material Triton-resistant
membrane fractions (TRM) (either fractionated from
whole cells or tissue) or Percoll gradient-isolated
plasma membranes (PM) cannot distinguish between
these very similar and sometimes associated membrane
microdomains, resulting in a preparation that
contains a mixture of caveolae, lipid rafts, and lipid
rafts associated with caveolae (
Fig. 4). When these
preparations are examined by EM, they are revealed to
contain individual caveolar vesicles in addition to larger vesiculated lipid rafts (
Fig. 5A) and even intact
large vesicular lipid rafts with a caveolae attached (
Fig.
5B,C) (Schnitzer
et al., 1995b). The attached caveola are
usually found inside the larger vesicle, but can also be
seen in an "inside-out" orientation outside the vesicle.
Immunogold EM showed that the larger vesicles but
not the attached caveolae could be labeled with goldconjugated
antibodies recognizing the GPI-AP carbonic
anhydrase, indicating that these larger vesicles contain lipid rafts. Moreover, these preparations
contain other detergent-resistant domains from other
subcellular organelles and even the plasma membrane
(
Fig. 3) (Lisanti
et al., 1994; Oh and Schnitzer, 1999;
Schnitzer
et al., 1995b). For instance, nuclear and Golgi
marker proteins, such as transportin and β-COP,
respectively, contaminate these preparations (Razandi
et al., 2002). Although caveolin-1 is an excellent marker
for labeling caveolae selectively on the cell surface, it
can also be present amply in exocytic vesicles of the
trans-Golgi network. In cultured cells, such as
Madin-Darby canine kidney cells, fibroblasts, or
endothelial cells, it can even be found primarily
in the Golgi. In addition, the membranes treated
with cold Triton X-100 will also contain protein
complexes resistant to detergent solubilization. For
example, it is well known that plasma membrane proteins
tethered to the cytoskeleton have increased
resistance to detergent solubilization as do possibly
other similar complexes, including focal adhesion sites
and intercellular junctional complexes. Other detergent-
resistant protein complexes may also float if they
retain sufficient lipids. Even in cells that lack both
caveolae and caveolin, TRM can readily be isolated as
rich in GPI-AP. The TRM from cells with and without
caveolae have very similar buoyant densities. It is
apparent that the physical characteristic of vesicle
buoyant density is unable to discriminate and thereby
separate caveolae from LR, which clearly explains
their coisolation in TRM, as well as other more recently
developed detergent-free procedures (Smart
et al.,
1995). Thus, isolation of detergent-resistant membrane
microdomains yields a heterogeneous fraction consisting
of a mixture of caveolar and noncaveolar
components.
 |
FIGURE 4 Isolation of detergent-resistant membranes without silica-coating procedure yields TRMs
containing both caveolae and lipid rafts. Nonsilica-based methodologies that isolate detergent-resistant
membranes by sucrose density centrifugation result in a heterogeneous preparation containing a mixture of
low-density microdomains as sheets or as partial or fully vesiculated forms. |
 |
FIGURE 5 Electron microscopy of nonsilica-isolated
detergentresistant
membranes (TRMs). (A) Membranes
isolated without
silica consist of larger vesicles
(150-700nm diameter) interspersed
with smaller caveolar
vesicles (<100nm) as well as nonvesiculated
linear
membrane sheets. (B and C) Caveolae were typically
observed
attached to a larger vesicle. Arrow: caveola
within a larger vesicle.
Arrowhead: "inside-out" caveola
attached to a larger
vesicle.
Magnification:
A,B = 10,000×; C = 20,000×. |
Caveolae can be isolated to near homogeneity using
as a starting material plasma membranes prepared
using the novel silica-coating procedure that bypasses
the problems associated with other techniques. Examination
of silica-coated plasma membranes by EM
reveals that the positively charged colloidal silica
particles form a strongly adherent layer over flat,
noninvaginated portions of the cell surface plasma
membrane (
Fig. 2) and do not enter the caveolae,
which appear amply present on the side of the
endothelial cell membrane not coated with silica (
Fig.
6A) (Oh and Schnitzer, 1998; Schnitzer
et al., 1995a,b).
This coating serves to stabilize the flat plasma membrane,
including the lipid raft domains, so that the
caveolae can be selectively detached from the plasma
membrane mechanically by homogenization, leaving
behind the plasma membrane proper (including lipid
rafts) still attached to the silica particles. The buoyant
caveolae can then be floated away from the high-density lipid raft/silica membrane pellicle by sucrose
gradient centrifugation. More than 95% of the caveolae
on the silica-coated plasma membranes are
removed and isolated in this manner as a rather
uniform homogeneous population of distinct flaskshaped
vesicles of approximately 80nm in diameter
(
Fig. 6B) (Schnitzer
et al., 1995b). Biochemical analysis
shows that the isolated caveolae represent specific
microdomains of the cell surface with their own
unique molecular topography (Schnitzer
et al.,
1995a,b,c). They are enriched in seven caveolar
markers established by immunogold EM: caveolin,
Ca
2+-ATPase, the glycolipid GM1, VAMP, eNOS,
dynamin, and the IP
3 receptor (McIntosh and
Schnitzer, 1999; Oh
et al., 1998; Rizzo
et al., 1998;
Schnitzer
et al., 1995b,c). In contrast, 5'NT, Band 4.1,
and β-actin are markedly depleted or absent from the
caveolae, despite being amply present in the silicacoated
plasma membrane starting material. More
recent work in the laboratory has utilized these membranes
successfully to generate and characterize monoclonal
antibodies specific for the caveolae, as assessed by both subfractionation and immunomicroscopic
analyses (McIntosh
et al., 2002).
Fig. 3A shows representative
immunoblots for various proteins of interest,
including some of the markers discussed earlier and
some of our new monoclonal antibodies.
 |
FIGURE 6 Electron micrographs of P (A) and V (B) membrane fractions after isolation. Electron
microscopy demonstrates the presence of significant numbers of caveolae on the intracellular side of the
plasma membrane not coated with silica (P fraction; A). Mechanical shearing of caveolae from the silicacoated
plasma membrane yields a homogeneous population of morphologically distinct caveolae with diameters
<90nm (V fraction; B). |
As a test to confirm the hypothesized key role of
silica coating in the isolation of caveolae separately
from lipid rafts, we have performed the caveolar
isolation on silica-isolated plasma membranes after
removing the silica coating under high salt conditions
(
Fig. 7). The resulting caveolae preparation closely
resembled the TRM fractions isolated without silica
coating. GPI-linked proteins not normally associated
with the highly purified V caveolar fraction, such as
5'-NT, were found in this isolate (data not shown).
Furthermore, electron microscopy revealed that
specimens, which appeared biochemically unpure by
this criterion, contained caveolae mixed with larger
vesicular structures very similar to those seen in
Fig.
5. Thus, the uniform silica coating at the cell surface
does indeed stabilize the plasma membrane by being
firmly attached on one side of the membrane to most, if not all, nonvesiculated regions. The silica coat
performs the essential function of preventing the
interaction of the LR with various detergents, as well
as the separation of noncaveolar detergent-resistant
microdomains from the cell membranes during shearing
to isolate caveolae. Without the silica coat, isolation
of homogeneous preparations of caveolae is not
possible.
 |
FIGURE 7 Silica coating prevents coisolation of caveolae and lipid rafts. Treatment of silica-coated
plasma membranes with high salt prior to separation of caveolae by homogenization results in a heterogeneous
mixture of membrane microdomains containing caveolae and lipid rafts alone or attached to each other
in partial
or fully vesiculated forms. |
In addition to allowing the isolation of highly purified
preparations of caveolae, the stable attachment
of silica particles to the detergent-resistant flat LR
domains provides a means to isolate lipid rafts away
from both caveolae and the plasmalemma proper (
Fig.
8) (Schnitzer
et al., 1995b). Silica-coated membranes
stripped of the caveolae are resedimented to form a
membrane pellet (P-V) during the centrifugation and
can be resuspended, treated with high salt to remove
the silica coating, and used to isolate low-density,
Triton-resistant lipid rafts by sucrose density centrifugation.
Figure 9 shows that each of our tissue subfractions
has a distinct protein profile and that caveolae and
LR differ considerably in this regard. Given that LR are
difficult to follow biophysically, they currently require
an operational definition based on their detergent
resistance. With our strict definition and differentiation
of caveolae and lipid rafts (see Section I), TRMs isolated
from plasma membranes stripped of caveolae (P-V)
should constitute lipid rafts. Because the starting preparation,
i.e., silica-coated plasma membranes, appears
minimally contaminated by intracellular membranes
(Oh and Schnitzer, 1999; Razandi
et al., 2002), the resulting
lipid raft preparation should be primarily, if not
exclusively, from the cell surface. Of course, future
experiments may provide further differentiation of
detergent-resistant domains beyond just LR.
 |
FIGURE 8 Isolation of LR from silica-coated plasma membranes stripped of caveolae. Because the silica
coating prevents the release of detergent-resistant, GPI-anchored protein microdomains, it is possible to
isolate these domains separately from caveolae. Incubation of silica-coated membranes stripped of caveolae
in the presence of high salt and polyacrylic acid followed by homogenization in Triton X-100 and sucrose
density centrifugation results in isolation of a membrane fraction containing membrane sheets as well as
vesicles >200nm in diameters. These membranes are enriched in GPI-AP, including 5'NT and carbonic
anhydrase. |
 |
FIGURE 9 One-dimensional protein analysis of
various membrane
subfraction. Proteins (5µg)
from the indicated membrane
fractions were
subjected to SDS-PAGE followed by silver
staining.
H, tissue homogenate; P, silica-coated
plasma membrane; V, caveolae;
P-V,
silica-coated plasma membrane stripped of
caveolae; LR,
lipid rafts. |
Using this methodology, we have shown that the
heterotrimeric protein G
q specifically concentrates in
caveolae, whereas G
s and G
i segregate preferentially to
lipid rafts. These results were confirmed by dual
immunofluorescence confocal microscopy to reveal
that, in cultured endothelial cells, G
q but not G
i or G
s colocalized with caveolin-marked caveolae, whereas
G
i and G
s, but not G
q, overlapped with folic acid receptor-
marked lipid rafts (Oh and Schnitzer, 2001). In
addition, we have shown that even in highly purified
plasma membranes with minimal contamination from
Golgi or other intracellular compartments, caveolae
and GPI-anchored proteins exist distinctly at the cell
surface and can actually be purified separately
(Schnitzer
et al., 1995b). Thus, the extra dimension to
the isolation process, namely the high-density silica
coat, takes advantage of the distinct morphological
characteristics of caveolae and lipid rafts (invaginated
vs flat) and renders a new fractionation technique
that is quite effective in separating two membrane
microdomains of similar buoyant density.
A reconstituted cell-free system has also been developed
to study further the dynamics and properties of caveolae (Schnitzer
et al., 1996). It shows that caveolae
are dynamic structures that can be induced to bud
from plasma membrane by GTP. Fission of caveolae
from the plasmalemma without any physical disruption
requires GTP hydrolysis and provides an alternative,
and possibly more physiological, source to isolate
caveolae. A comparison of GTP-induced budded caveolae
with caveolae isolated via the silica-coating technique
reveals that both isolates yield similar protein
profiles (Schnitzer
et al., 1996).
Another widely used procedure leading to a similar
isolate as TRM involves detergent-free sonication of
plasma membranes isolated on a Percoll gradient
before Optiprep gradient centrifugation to collect fractions
over a wide range of densities (10-20%) (Smart
et al., 1995). This is then concentrated using a step gradient
consisting of 5% layered over 23% to yield a
caveolin-rich fraction (AC) that has been characterized
as quite similar to TRM (Oh and Schnitzer, 1999).
Further comparative investigation of the Optiprepbased
caveolae isolate AC vs the silica-based isolate
V by immunoisolation using caveolin-1 antibodies
showed that-50% vs 95%, respectively, of the material bound to the caveolin-1-antibody magnetic beads (Oh
and Schnitzer, 1999).
Figure 3B shows a comparative
Western analysis for specific proteins in each fraction.
AC clearly contains proteins of the cytoskeleton, lipid
rafts, Golgi, and nucleus, but after immunoisolation,
the protein profile is identical to that of silica-based
caveolae isolate (
Fig. 3, compare fraction B to V).
Almost certainly the source of contamination in
Optiprep-based caveolar isolates stems from the use of
PM as a starting material. As discussed earlier, PM
contains a mixture of cell membranes in addition
to plasma membranes, such as Golgi, ER, nuclear,
and mitochondrial, that are composed of multiple
microdomains of different densities. Therefore, strategies
that use flotation of membranes to isolate
caveolae from this preparation naturally coisolate
contaminating membrane fragments of similar low
density to yield a caveolin-rich membrane fraction that
also contains a significant amount of noncaveolar
membranes. Immunoisolation should be used as a last
step to validate more definitively the expression of a
given protein in caveolae.
References
Brown, D. A., and London, E. (2000). Structure and function of
sphingolipid- and cholesterol-rich membrane rafts.
J. Biol. Chem.
275, 17221-17224.
Brown, D. A., and Rose, J. K. (1992). Sorting of GPI-anchored proteins
to glycolipid-enriched membrane subdomains during
transport to the apical cell surface.
Cell 68, 533-544.
Chang, W. J., Ying, Y. S., Rothberg, K. G., Hooper, N. M., Turner, A.
J., Gambliel, H. A., De Gunzburg, J., Mumby, S. M., Gilman, A.
G., and Anderson, R. G. (1994). Purification and characterization
of smooth muscle cell caveolae.
J Cell Biol.
126, 127-138.
Field, K. A., Holowka, D., and Baird, B. (1995). Fc epsilon RImediated
recruitment of p53/561yn to detergent-resistant membrane
domains accompanies cellular signaling.
Proc. Natl. Acad.
Sci. USA 92, 9201-9205.
Fra, A. M., Williamson, E., Simons, K., and Parton, R. G. (1995). De
novo formation of caveolae in lymphocytes by expression of
VIP21-caveolin.
Proc. Natl. Acad. Sci. USA 92, 8655-8659.
Fujimoto, T. (1996). GPI-anchored proteins, glycosphingolipids, and
sphingomyelin are sequestered to caveolae only after crosslinking.
J. Histochem. Cytochem.
44, 929-941.
Gorodinsky, A., and Harris, D. A. (1995). Glycolipid-anchored proteins
in neuroblastoma cells form detergent-resistant complexes
without caveolin.
J. Cell Biol.
129, 619-627.
Lisanti, M. P., Scherer, P. E., Vidugiriene, J., Tang, Z., Hermanowski-
Vosatka, A., Tu, Y. H., Cook, R. E, and Sargiacomo, M. (1994).
Characterization of caveolin-rich membrane domains isolated
from an endothelial-rich source: Implications for human disease.
J. Cell Biol.
126, 111-126.
Liu, J., Oh, P., Horner, T., Rogers, R. A., and Schnitzer, J. (1997). Organized
cell surface signal transduction in caveolae distinct from
GPI-anchored protein microdomains.
J. Biol. Chem.
272,
7211-7222.
Mayor, S., Rothberg, K. G., and Maxfield, E R. (1994). Sequestration
of GPI-anchored proteins in caveolae triggered by cross-linking.
Science 264, 1948-1951.
McIntosh, D. P., and Schnitzer, J. E. (1999). Caveolae require intact
VAMP for targeted transport in vascular endothelium.
Am. J.
Physiol.
277, H2222-2232.
McIntosh, D. P., Tan, X.-Y., Oh, P., and Schnitzer, J. E. (2002). Targeting
endothelium and its dynamic caveolae for tissue-specific
transcytosis
in vivo: A pathway to overcome cell barriers to drug
and gene delivery.
Proc. Natl. Acad. Sci. USA 99, 1996-2001.
Monier, S., Parton, R. G., Vogel, E, Behlke, J., Henske, A., and
Kurzchalia, T. V. (1995). VIP21-caveolin, a membrane protein
constituent of the caveolar coat, oligomerizes
in vivo and
in vitro.
Mol. Biol. Cell 6, 911-927.
Montixi, C., Langlet, C., Bernard, A. M., Thimonier, J., Dubois, C.,
Wurbel, M. A., Chauvin, J. P., Pierres, M., and He, H. T. (1998).
Engagement of T cell receptor triggers its recruitment to lowdensity
detergent-insoluble membrane domains.
EMBO J.
17,
5334-5348.
Oh, P., McIntosh, D. P., and Schnitzer, J. E. (1998). Dynamin at the
neck of caveolae mediates their budding to form transport vesicles
by GTP-driven fission from the plasma membrane of
endothelium.
J. Cell Biol.
141, 101-114.
Oh, P., and Schnitzer, J. E. (1998). Isolation and subfractionation of
plasma membranes to purify caveolae separately from glycosylphosphatidylinositol-
anchored protein microdomain.
In Cell
Biology: A Laboratory Handbook (J. Celis, ed.), Vol. 2, pp. 34-36.
Academic Press, Orlando.
Oh, P., and Schnitzer, J. E. (1999). Immunoisolation of caveolae with
high affinity antibody binding to the oligomeric caveolin cage:
Toward understanding the basis of purification [published
erratum appears in J. Biol. Chem. 274(41), 29582 (1999)].
J. Biol.
Chem.
274, 23144-23154.
Oh, P., and Schnitzer, J. E. (2001). Segregation of heterotrimeric G
proteins in cell surface microdomains: Gq binds caveolin to concentrate in caveolae whereas Gi and Gs target lipid rafts by
default.
Mol. Biol. Cell 12, 685-698.
Razandi, M., Oh, P., Pedram, A., Schnitzer, J., and Levin, E. R. (2002).
ERs associate with and regulate the production of caveolin:
Implications for signaling and cellular actions.
Mol. Endocrinol.
16, 100-115.
Rizzo, V., McIntosh, D. P., Oh, P., and Schnitzer, J. E. (1998). In situ
flow activates endothelial nitric oxide synthase in luminal caveolae
of endothelium with rapid caveolin dissociation and
calmodulin association.
J. Biol. Chem.
273, 34724-34729.
Rothberg, K. G., Ying, Y. S., Kolhouse, J. E, Kamen, B. A., and Anderson,
R. G. (1990). The glycophospholipid-linked folate receptor
internalizes folate without entering the clathrin-coated pit endocytic
pathway.
J. Cell Biol.
110, 637-649.
Sargiacomo, M., Sudol, M., Tang, Z., and Lisanti, M. P. (1993). Signal
transducing molecules and glycosyl-phosphatidylinositol-linked
proteins form a caveolin-rich insoluble complex in MDCK cells.
J. Cell Biol.
122, 789-807.
Schnitzer, J. E., Liu, J., and Oh, P. (1995a). Endothelial caveolae have
the molecular transport machinery for vesicle budding, docking
and fusion including VAMP, NSF, SNAP, annexins and GTPases.
J. Biol. Chem.
270, 14399-14404.
Schnitzer, J. E., McIntosh, D. P., Dvorak, A. M., Liu, J., and Oh, P.
(1995b). Separation of caveolae from associated microdomains of
GPI-anchored proteins.
Science 269, 1435-1439.
Schnitzer, J. E., and Oh, P. (1996). Aquaporin-1 in plasma membrane
and caveolae provides mercury-sensitive water channels across
lung endothelium.
Am. J. Physiol.
270, H416-422.
Schnitzer, J. E., Oh, P., Jacobson, B. S., and Dvorak, A. M. (1995c).
Caveolae from luminal plasmalemma for rat lung endothelium:
Microdomains enriched in caveolin, Ca2+-ATPase and inositol
trisphosphate receptor.
Proc. Natl. Acad. Sci. USA 92, 1759-1763.
Schnitzer, J. E., Oh, P., and McIntosh, D. P. (1996). Role of GTP
hydrolysis in fission of caveolae directly from plasma membrane.
Science 274, 239-242.
Shenoy-Scaria, A. M., Kwong, J., Fujita, T., Olszowy, M. W., Shaw,
A. S., and Lublin, D. M. (1992). Signal transduction through
decay-accelerating factor: Interaction of glycosyl-phosphatidylinositol
anchor and protein tyrosine kinases p561ck and p59fyn 1.
J. Immunol.
149, 3535-3541.
Smart, E. J., Ying, Y. S., Mineo, C., and Anderson, R. G. (1995). A
detergent-free method for purifying caveolae membrane from
tissue culture cells.
Proc. Natl. Acad. Sci. USA 92, 10104-10108.
Stefanova, I., Horejsi, V., Ansotegui, I. J., Knapp, W., and Stockinger,
H. (1991). GPI-anchored cell-surface molecules complexed to
protein tyrosine kinases.
Science 254, 1016-1019.
Xavier, R., Brennan, T., Li, Q., McCormack, C., and Seed, B. (1998).
Membrane compartmentation is required for efficient T cell activation.
Immunity 8, 723-732.
Ying, Y. S., Anderson, R. G., and Rothberg, K. G. (1992). Each caveola
contains multiple glycosyl-phosphatidylinositol-anchored membrane
proteins.
Cold Spring Harb. Symp. Quant. Biol.
57, 593-604.